Anuh Pharma Limited (ANUHPHR) AI Stock Analysis

• Market Cap: ₹7.88B
• Dividend Yield: 1.93%
• Average Volume (3M): 6.00K
• Price to Earnings (P/E): 20.3
• Beta (1Y): 0.65
• Revenue Growth: 14.09%
• EPS Growth: -34.41%
• Country: IN
• Employees: 295
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.76
• Shares Outstanding: 100,224,000
• 10 Day Avg. Volume: 6,374
• 30 Day Avg. Volume: 5,996
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 64 Neutral
• Price Target: ₹85.00 ▲(9.63% Upside)

Anuh Pharma Limited's strong financial performance, characterized by revenue growth and a stable balance sheet, is a key strength. However, technical indicators suggest bearish momentum, and valuation metrics indicate the stock is fairly valued. The lack of earnings call data and corporate events limits further insights.

Positive Factors

Revenue Growth

Consistent revenue growth indicates the company's ability to expand its market presence and strengthen its competitive position over time.

Balance Sheet Health

A strong balance sheet with low leverage enhances financial stability and provides flexibility for future investments and growth opportunities.

Gross Profit Margin

Sustained gross profit margins suggest efficient cost control, which supports long-term profitability and competitive pricing strategies.

Negative Factors

Profitability Margin Pressure

Declining margins could impact the company's ability to sustain profitability, affecting long-term financial health and investment capacity.

Free Cash Flow Volatility

Inconsistent free cash flow can limit the company's ability to fund operations and growth initiatives, posing a risk to financial stability.

Net Profit Margin Decline

A declining net profit margin may indicate rising costs or pricing pressures, which could undermine long-term earnings potential.

Anuh Pharma Limited Business Overview & Revenue Model

Company Description

Anuh Pharma Limited engages in the manufacture and sale of bulk drugs and chemicals in India. It offers active pharmaceutical ingredients, including macrolides, anti-TB, anti-bacterial, anti-asthmatics, anti-diabetics, intermediates, expectorant, quinolones, anti-malarial, anti-gout, anti-biotic, anti-platelet, and antihistamines; and corticosteroids, including anti-inflammatory, immunosuppressant, anti-pruritic, anti-mitotic. The company also develops products, such as coagulants, gastrointestinal, anti convulsants, and cholesterol drugs. It also exports its products. The company was incorporated in 1960 and is headquartered in Mumbai, India.

How the Company Makes Money

Anuh Pharma Limited generates revenue through multiple streams, primarily by selling its pharmaceutical products, which include both generic and branded medications. The company partners with healthcare providers, distributors, and pharmacies to ensure its products reach a wide market. Additionally, Anuh Pharma may engage in contract manufacturing agreements, providing production services to other pharmaceutical companies. Significant revenue is also derived from research collaborations and licensing agreements for its proprietary formulations. As the company continues to expand its product pipeline and improve operational efficiencies, it aims to enhance its market position and drive earnings growth.

Anuh Pharma Limited Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	6.62B	6.47B	5.27B	4.87B
Gross Profit	1.62B	1.60B	1.26B	1.09B
EBITDA	703.64M	872.47M	573.89M	520.43M
Net Income	473.52M	600.58M	361.80M	305.61M
Balance Sheet
Total Assets	5.07B	4.46B	4.05B	3.47B
Cash, Cash Equivalents and Short-Term Investments	734.15M	622.56M	530.77M	252.65M
Total Debt	108.86M	26.93M	9.07M	42.23M
Total Liabilities	1.81B	1.54B	1.64B	1.33B
Stockholders Equity	3.26B	2.91B	2.41B	2.14B
Cash Flow
Free Cash Flow	169.79M	79.08M	523.51M	272.49M
Operating Cash Flow	371.25M	129.25M	539.02M	288.64M
Investing Cash Flow	-199.09M	9.18M	-434.84M	-78.17M
Financing Cash Flow	-48.60M	-85.68M	-122.87M	-194.49M

Anuh Pharma Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 77.53
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ANUHPHR, the sentiment is Negative. The current price of 77.53 is below the 20-day moving average (MA) of 78.94, below the 50-day MA of 81.70, and below the 200-day MA of 88.43, indicating a bearish trend. The MACD of -0.94 indicates Negative momentum. The RSI at 44.51 is Neutral, neither overbought nor oversold. The STOCH value of 18.38 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ANUHPHR.

Anuh Pharma Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ANUHPHR	64 Neutral	₹7.88B	20.35	―	1.93%	14.09%	-34.41%
WANBURY	64 Neutral	₹7.82B	15.07	―	―	8.92%	-5.56%
KILITCH	57 Neutral	₹5.89B	19.80	―	―	32.95%	67.39%
KOPRAN	57 Neutral	₹6.29B	35.69	―	2.32%	-6.96%	-66.75%
THEMISMED	54 Neutral	₹9.45B	-34.56	―	0.49%	-18.86%	-150.92%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%